期刊文献+

ITP患者雷公藤内酯醇对浆细胞样树突细胞影响的研究

Study on the Effects of Triptolide on ITP Patients with Plasmacytoid Dendritic Cells
下载PDF
导出
摘要 目的:探究原发免疫性血小板减少症(ITP)患者中雷公藤内酯醇的应用对浆细胞样树突细胞功能及成熟的影响情况。方法:截取我院2012年3月-2013年1月共60例ITP患者,按病情情况分为ITP初期组(28例)及ITP完全缓解组(32例),并选取同期体检正常人群(30例),对比各组患者间临床资料差异性。结果:初治组与缓解组在加入不同浓度的雷公藤内酯醇中,IFN-α、IL-6、TNF-α、CD11C、CD80、CD86水平在高浓度均较低浓度组水平降低(P〈0.05),初治组对比缓解组及正常组水平升高(P〈0.05)。结论:对pDC向mDC的转化过程中雷公藤内酯醇存在减少分泌细胞因子的作用,但其确切机制有待进一步研究。 Objective:To explore the primary immune thrombocytopenia (ITP) in patients with application of triptolide on plasmacytoid dendritic cell function and mature effect;Methods:In our hospital from 2012 March to January-2013 total of 60 cases of ITP patients, according to the illness into primary ITP group (28 cases) and ITP in complete remission group (32 cases), and select the normal physical examination (30 cases), groups were compared between patients clinical data difference. Results:The initial treatment group and remission group in triptolide by adding different concentrations of IFN-α, IL-6, reduce, TNF-α, CD11C, CD80, CD86 levels in high concentrations are low concentration group (P〈0.05), initial treatment group compared to ease the rising group and normal group level (P〈0.05). Conclusion:Triptolide on pDC to mDC conversion process has reduced the secretion of cytokines, but its exact mechanism remains to be further studie.
作者 安婕 唐雯
出处 《中国医药导刊》 2014年第4期712-713,共2页 Chinese Journal of Medicinal Guide
关键词 雷公藤内酯醇 原发免疫性血小板减少症 浆细胞样树突细胞 Triptolide Primary immune thrombocytopenia Plasmacytoid dendritic cells
  • 相关文献

参考文献10

二级参考文献80

  • 1赵军宁,王晓东,彭龙玲,温志坚.雷公藤多甙预防大鼠肾病的体视学研究[J].中国药理学通报,1995,11(6):468-472. 被引量:15
  • 2朱可建,林爱华,金纳,周强,叶俊,虞海燕,程浩.雷公藤内酯醇对人树突状细胞分化成熟的抑制[J].中华微生物学和免疫学杂志,2007,27(4):330-331. 被引量:7
  • 3Ding G S.Clin.Ther.,1987,9(4):345~357.
  • 4Tao X,Cush J J,Garret M,Lipsky P E.J.Rheumatol.,2001,28(10):2160~2167.
  • 5Tao X,Younger J,Fan F Z,Wang B,Lipsky P E.Arthritis Rheum,2002,46(7):1735~1743.
  • 6Lu H,Hachida M,Enosawa S,Li X K,Suzuki S,Koyanagi H.Transplant Proc.,1999,31(5):2056~2057.
  • 7Lue Y,Sinha Hikim A P,Wang C,Leung A,Baravarian S,Reutrakul V,Sangsawan R,Chaichana S,Swerdloff R S.J.Androl.,1998,19(4):479~486.
  • 8Wang X,Matta R,Shen G,Nelin L D,Pei D,Liu Y.J.Mol.Med.,2006,84(5):405~415.
  • 9Wan C K,Wang C,Cheung H Y,Yang M,Fong W F.Cancer Lett.,2006,241(1):31~41.
  • 10Carter B Z,Mak D H,Schober W D,McQueen T,McQueen T,Harris D,Estrov Z,Evans R L,Andreeff M.Blood,2006,108(2):630~637.

共引文献136

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部